Edition:
United Kingdom

Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

2.40USD
18 May 2018
Change (% chg)

$-0.03 (-1.23%)
Prev Close
$2.43
Open
$2.45
Day's High
$2.50
Day's Low
$2.37
Volume
51,763
Avg. Vol
34,212
52-wk High
$2.71
52-wk Low
$1.00

Latest Key Developments (Source: Significant Developments)

Bellerophon Therapeutics Q1 Shr Loss $0.04
Thursday, 10 May 2018 

May 10 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.BELLEROPHON THERAPEUTICS Q1 BASIC EARNINGS PER SHARE $0.07 .BELLEROPHON THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.04.  Full Article

Bellerophon Reaches Agreement With FDA On Study Design Of Phase 2b Trial Of INOpulse
Tuesday, 8 May 2018 

May 8 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON REACHES AGREEMENT WITH FDA ON STUDY DESIGN OF PHASE 2B TRIAL OF INOPULSE® FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.BELLEROPHON REACHES AGREEMENT WITH FDA ON STUDY DESIGN OF PHASE 2B TRIAL OF INOPULSE® FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.BELLEROPHON THERAPEUTICS - PHASE 2B STUDY TO BE A DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL IN ABOUT 90 PH-COPD PATIENTS.BELLEROPHON THERAPEUTICS - PRIMARY END POINT OF STUDY WILL BE SIX-MINUTE WALKING DISTANCE, STUDY TO ALSO ASSESS MULTIPLE SECONDARY ENDPOINTS.  Full Article

Bellerophon Therapeutics reports Q3 loss per share $0.22
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon provides business update and reports third quarter 2017 financial results.Q3 loss per share $0.22.Says ‍ phase 2a study for inopulse met its primary endpoint​.  Full Article

Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filing
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon Therapeutics Inc files to say selling stockholders may offer and resell up to 38.9 million shares of co's common stock - SEC filing.Bellerophon Therapeutics Inc - the selling stockholders will receive all of the proceeds from any sales of the shares offered.  Full Article

Bellerophon announces $23 million private placement
Wednesday, 27 Sep 2017 

Sept 27 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon announces $23 million private placement.Bellerophon Therapeutics Inc - ‍financing was led by Puissance Capital Management and Venrock Healthcare Capital Partners​.Bellerophon Therapeutics Inc - will sell about 19.4 million shares of stock, warrants to purchase about 19.4 million shares of stock for about $23.4 million.  Full Article

Bellerophon announces positive top line Phase 2 data of INOpulse
Tuesday, 5 Sep 2017 

Sept 5 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon announces positive top line Phase 2 data of INOpulse for treatment of Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease.Bellerophon Therapeutics Inc - ‍acute results showed a statistically significant increase in blood vessel volume on INO compared to baseline​.Bellerophon Therapeutics Inc - ‍study therapy was well tolerated with no related safety concerns​.Bellerophon Therapeutics Inc - ‍is currently conducting a Phase 3 trial for INOpulse for treatment of Pulmonary Arterial Hypertension​.Bellerophon Therapeutics Inc - ‍top-line data for Phase 3 trial of INOpulse expected in 2018​.  Full Article

Bellerophon reports Q2 loss per share $0.12
Monday, 7 Aug 2017 

Aug 7 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.12.Bellerophon Therapeutics - Anticipate reporting top line results for inovation-1 phase 3 trial in PAH in 2018.  Full Article

Bellerophon announces FDA agreement on phase 2B study design for Inopulse
Thursday, 3 Aug 2017 

Aug 3 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon announces FDA agreement on phase 2B study design for Inopulse in pulmonary hypertension associated with interstitial lung disease (PH-ILD).Bellerophon Therapeutics -‍met with FDA in June to present positive results from its recently completed phase 2A study in idiopathic pulmonary fibrosis​.Bellerophon Therapeutics Inc - ‍agency accepted co's proposed phase 2B study design as well as an ind application to assess effect of inopulse​.  Full Article

CVI Investments reports 5.7 percent passive stake in Bellerophon Therapeutics as of May 10
Thursday, 18 May 2017 

May 18 (Reuters) - CVI Investments Inc :CVI Investments Inc reports 5.7 percent passive stake in Bellerophon Therapeutics Inc as of May 10, 2017 - SEC filing.  Full Article

Bellerophon Q1 loss per share $0.60
Monday, 15 May 2017 

May 15 (Reuters) - Bellerophon Therapeutics Inc ::Bellerophon reports first quarter 2017 financial results and provides business update.Q1 loss per share $0.60.Bellerophon Therapeutics - believes that as of march 31, 2017, it has sufficient funds to satisfy its operating cash needs for at least next 12 months.Bellerophon Therapeutics - at March 31, 2017, co had cash and cash equivalents, restricted cash and marketable securities of $17.1 million compared to $20.5 million at December 31, 2016.  Full Article

BRIEF-Bellerophon Therapeutics Q1 Shr Loss $0.04

* BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS